Search

Displaying results 5741 - 5750 of 8974 in total
  1. Drug

    MaxAdFVIII

    go.drugbank.com/drugs/DB17713
    Experimental

    First developed by GenStar, it is being investigated for the treatment of hemophilia.

  2. Drug

    Befunolol

    go.drugbank.com/drugs/DB09013
    Experimental

    Befunolol is a beta blocker introduced in 1983 by Kakenyaku Kakko. It is currently in experimental status, and is being tested for the management of open angle glaucoma.

  3. Drug

    RCT1100

    go.drugbank.com/drugs/DB18830
    Investigational

    RCT1100 is an investigational mRNA-based therapeutic that aims to treat primary ciliary dyskinesia caused by pathogenic mutations in DNAI1.[L50788]

  4. Drug

    ENTR-601-44

    go.drugbank.com/drugs/DB17836
    Investigational

    Developed by Entrada Therapeutics, it was investigated for the treatment of Duchenne muscular dystrophy.[L46641]

  5. Drug

    PAS-004

    go.drugbank.com/drugs/DB18611
    Investigational

    PAS-004 is an allosteric MEK 1/2 inhibitor being developed by Pasithea Therapeutics. It is being investigated for the treatment of neurofibromatosis 1 and Noonan syndrome.

  6. Drug

    Tyramine

    go.drugbank.com/drugs/DB08841
    InvestigationalNutraceutical

    An important characteristic of this product is its impediment to cross the blood-brain barrier which restrains its side effects to only nonpsychoactive peripheral sympathomimetic effects. … Tyramine acts by inducing the release of catecholamine.

  7. Drug

    Onercept

    go.drugbank.com/drugs/DB06495
    Investigational

  8. Drug

    KBP-COVID-19

    go.drugbank.com/drugs/DB15858
    Investigational

    KBP cloned COVID-19’s genetic sequence, identified a potential antigen, and then inserted it into tobacco plants for reproduction. … As of July 2020, KBP is conducting a Phase 1/2 clinical trial to evaluate the safety and immunogenicity of KBP-COVID-19 vaccine in healthy patients (NCT04473690).

  9. Drug

    CG7870

    go.drugbank.com/drugs/DB04981
    Investigational

    CG7870 is an oncolytic virus therapy for prostate cancer. … It is a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer.

  10. Drug

    TBC-3711

    go.drugbank.com/drugs/DB05407
    Investigational

    TBC3711 is a next-generation endothelin antagonist that is being studied through oral and intravenous formulations by Encysive Pharmaceuticals.